{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:41:37Z","timestamp":1764603697060,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejmech.2020.112478","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T20:27:23Z","timestamp":1591993643000},"page":"112478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents"],"prefix":"10.1016","volume":"201","author":[{"given":"Costanza","family":"Ceni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Catarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Varano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Dal","family":"Ben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Marucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Buccioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Volpini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Gratteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Colotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112478_bib1","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1568026619666190619115735","article-title":"Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases","volume":"19","author":"Ivasiv","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib2","first-page":"842","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112478_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/bph.13763","article-title":"Pathological overproduction: the bad side of adenosine","volume":"174","author":"Borea","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112478_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112478_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2020.112478_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumors as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112478_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112478_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic anhydrase inhibition and the management of hypoxic tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2020.112478_bib9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging hypoxic tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2020.112478_bib10","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112478_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14728222.2019.1630380","article-title":"Targeting A3 and A2A adenosine receptors in the fight against cancer","volume":"23","author":"Merighi","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2020.112478_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2017.00888","article-title":"Inhibition of A2A adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455","volume":"8","author":"Gessi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112478_bib13","article-title":"Adenosine A2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","author":"Fong","year":"2019","journal-title":"Canc. Discov."},{"key":"10.1016\/j.ejmech.2020.112478_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/17460441.2017.1253677","article-title":"Advances in structure-based drug discovery of carbonic anhydrase inhibitors","volume":"12","author":"Supuran","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112478_bib15","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1021\/acs.jmedchem.6b01068","article-title":"Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives: new highly potent A2A adenosine receptor inverse agonists with antinociceptive activity","volume":"59","author":"Varano","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejmech.2016.09.076","article-title":"Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: structural exploration to target the A3 and A2A subtypes","volume":"125","author":"Poli","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/14756366.2016.1247060","article-title":"The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity Profiles","volume":"32","author":"Squarcialupi","year":"2017","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib18","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1021\/acs.jmedchem.7b00457","article-title":"The 1,2,4-triazolo[4,3-a]pyrazin-3-one as a versatile scaffold for the design of potent adenosine human receptor antagonists. Structural investigations to target the A2A Receptor","volume":"60","author":"Falsini","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib19","first-page":"3688","article-title":"Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists\/inverse agonists, Bioorg","volume":"26","author":"Varano","year":"2018","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejmech.2018.06.020","article-title":"Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2A adenosine receptor","volume":"155","author":"Varano","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bmcl.2018.12.062","article-title":"Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity","volume":"29","author":"Varano","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112478_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bioorg.2019.03.046","article-title":"Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against \u03b2-amyloid-induced neurotoxicity in SH-SY5Y cells","volume":"87","author":"Falsini","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib23","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1021\/acs.jmedchem.9b00106","article-title":"Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity","volume":"62","author":"Betti","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib24","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1021\/acs.jmedchem.9b00778","article-title":"Antioxidant-conjugated 1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives: highly potent and selective human A2A adenosine receptor antagonists possessing protective efficacy in neuropathic pain","volume":"62","author":"Falsini","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejmech.2018.01.033","article-title":"Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: new scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII","volume":"146","author":"Bonardi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib26","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1021\/acs.jmedchem.7b00766","article-title":"3-Hydroxy-1H-quinazoline-2,4-dione as a new scaffold to develop potent and selective inhibitors of the tumor-associated carbonic anhydrases IX and XII","volume":"60","author":"Falsini","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib27","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/molecules21121649","article-title":"Phenol and poliphenols as carbonic anhydrases inhibitors","volume":"21","author":"Karioti","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112478_bib28","first-page":"1799","article-title":"A\u00a0New Method for the Synthesis of 1-Aryl-1,2,4-Triazole Derivatives","volume":"vol. 11","author":"Matiychuk","year":"2011","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2020.112478_bib29","unstructured":"M. Scobie, O. Wallner, T. Koolmeister, K.S.A. Vallin, C.M. Henriksson, S. Jacques, E. Homan, T. Helleday, Diaminopyrimidines as MTH-1 Inhibitors for Treatment of Cancer and Their Preparation, WO 2015187088, A1 20151210, page 127."},{"key":"10.1016\/j.ejmech.2020.112478_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/00397910601039226","article-title":"Preparation of monoalkyl terephthalates: an overview","volume":"37","author":"Chenot","year":"2007","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2020.112478_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cmdc.201000530","article-title":"Design, synthesis, and in\u00a0vitro antifungal activity of 1-[(4-Substituted-benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols","volume":"6","author":"Guillon","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112478_bib32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1021\/jm00125a028","article-title":"Peripherally acting enkephalin analogues. 2. Polar tri- and tetrapeptides","volume":"32","author":"Hardy","year":"1989","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41467-017-00630-4","article-title":"Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons","volume":"8","author":"Weinert","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112478_bib34","unstructured":"Molecular Operating Environment, C.C.G., Inc, 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3."},{"key":"10.1016\/j.ejmech.2020.112478_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.112478_bib36","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b01389","article-title":"Benzenesulfonamides incorporating flexible triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations","volume":"59","author":"Nocentini","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib37","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b01343","article-title":"Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX","volume":"58","author":"Leitans","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib38","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.161301298","article-title":"Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells","volume":"98","author":"Whittington","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"year":"2018","series-title":"Schr\u00f6dinger Suite Release 2019-1","key":"10.1016\/j.ejmech.2020.112478_bib39"},{"key":"10.1016\/j.ejmech.2020.112478_bib40","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/chem.201805039","article-title":"Phosphorus versus sulfur: discovery of benzenephosphonamidates as versatile sulfonamide-mimic chemotypes acting as carbonic anhydrase inhibitors","volume":"25","author":"Nocentini","year":"2019","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2020.112478_bib41","article-title":"Bioisosteric development of multi-target nonsteroidal anti-inflammatory drug - carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis","author":"Bua","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib42","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1002\/chem.201800941","article-title":"Deciphering the mechanism of human carbonic anhydrases inhibition with sulfocoumarins: computational and experimental studies","volume":"24","author":"Nocentini","year":"2018","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2020.112478_bib43","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/cmdc.201500595","article-title":"The length and flexibility of the 2-substituent of 9-ethyladenine derivatives modulate affinity and selectivity for the human A2A adenosine receptor","volume":"11","author":"Thomas","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112478_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1389557516666160808120207","article-title":"Overview on radiolabel-free in\u00a0vitro assays for GPCRs","volume":"17","author":"Buccioni","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11302-011-9245-8","article-title":"Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17","volume":"7","author":"Buccioni","year":"2011","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2020.112478_bib46","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.5b01720","article-title":"Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins","volume":"59","author":"Ferraroni","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib48","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1021\/jm9901879","article-title":"Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl\/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route","volume":"42","author":"Scozzafava","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112478_bib49","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bmc.2015.02.027","article-title":"A\u00a0class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects","volume":"23","author":"Carta","year":"2015","journal-title":"Bioorg. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:14:19Z","timestamp":1759328059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420304499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":49,"alternative-id":["S0223523420304499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112478","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112478"}}